Drug Shortage Report for MYLAN-RIVASTIGMINE PATCH 10
Report ID | 223273 |
Drug Identification Number | 02423421 |
Brand name | MYLAN-RIVASTIGMINE PATCH 10 |
Common or Proper name | RIVASTIGMINE |
Company Name | MYLAN PHARMACEUTICALS ULC |
Market Status | MARKETED |
Active Ingredient(s) | RIVASTIGMINE |
Strength(s) | 9.5MG |
Dosage form(s) | PATCH |
Route of administration | TRANSDERMAL TRANSDERMAL |
Packaging size | 30 Patches |
ATC code | N06DA |
ATC description | ANTI-DEMENTIA DRUGS |
Reason for shortage | Disruption of the manufacture of the drug. |
Anticipated start date | 2024-04-01 |
Actual start date | 2024-04-01 |
Estimated end date | 2024-04-10 |
Actual end date | 2024-04-11 |
Shortage status | Resolved |
Updated date | 2024-04-16 |
Company comments | |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 85 ADVANCE ROAD ETOBICOKE, ONTARIO CANADA M8Z 2S6 |
Company contact information | Mylan Pharmaceuticals ULC, 85 Advance Road, Etobicoke, ON, M8Z 2S6 |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v9 | 2024-04-16 | French | Compare |
v8 | 2024-04-16 | English | Compare |
v7 | 2024-04-09 | French | Compare |
v6 | 2024-04-09 | English | Compare |
v5 | 2024-04-02 | English | Compare |
v4 | 2024-04-01 | French | Compare |
v3 | 2024-04-01 | English | Compare |
v2 | 2024-03-25 | French | Compare |
v1 | 2024-03-25 | English | Compare |
Showing 1 to 9 of 9